Our Team
Our success is driven by a world-class team of professionals. With seasoned management and a board with extensive experience in both Big Pharma and early-stage biotech, we are well-equipped to navigate the complexities of drug development and generate substantial value for all stakeholders.
Management team
Alan Cookson, PHD
CEO
Andrew Galazka, MD
Chairman and acting CMO
Lionel Brodard
CFO
Marc Criton, PHD
COO
Benedicte Fauvel, PHD
VP, Head of Pre-clinical Development
Marc Bonneville, PhD
CSO
BOARD OF DIRECTORS
Andrew Galazka, MD
Chairman and acting CMO
Elsy Boglioli
Board member
Alexandre LeBeaut, MD
Board member
Julie Puype
Board member
Eric Falcand
Board member
WORLD CLASS GBM CLINICAL & SCIENTIFIC ADVISORY BOARD
Prof. Roger Stupp
GBM oncologist & researcher
Andrew Galazka, MD
Chairman and acting CMO
Prof. Mitchel Berger
GBM surgeon & researcher
Prof. Nicolas de Tribolet
GBM surgeon & researcher
Prof. Ariel Ruiz i Altaba
Neurodevelopmental and cancer biology expert
Prof. Pierre Magistretti
Neurologist & biomarkers expert
PLATFORM SCIENTIFIC FOUNDERSā
Martin Villalba
Researcher
Pierre Martineau, PHD
Researcher
Javier Hernandez, PHD
Researcher
Bruno Robert, PhD
Researcher
Prof. Christian Jorgensen
Researcher
- MedXCell
Cytea bio - a pipeline company of MedxcellĀ
CYTEA BIO is a pipeline company of MedXCell, a Swiss venture builder. CYTEA BIO has been founded and financed by MedXCell, gaining access to crucial skills to advance its programs. CYTEA BIO Ā is now in the process of raising its first external funding.
